Beam Therapeutics Stock Today

BEAM
 Stock
  

USD 43.01  1.27  2.87%   

Market Performance
0 of 100
Odds Of Distress
Less than 2
Beam Therapeutics is selling for 43.01 as of the 28th of November 2022. This is a -2.87 percent down since the beginning of the trading day. The stock's lowest day price was 42.58. Beam Therapeutics has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Beam Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of March 2022 and ending today, the 28th of November 2022. Click here to learn more.
Fiscal Year End
December
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
6th of February 2020
Category
Healthcare
Classification
Health Care
ISIN
US07373V1052
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. Beam Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 70.47 M outstanding shares of which 13.01 M shares are currently shorted by private and institutional investors with about 13.39 trading days to cover. More on Beam Therapeutics

Beam Therapeutics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Beam Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Beam Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Beam Therapeutics generated a negative expected return over the last 90 days
Beam Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 91.95 M. Net Loss for the year was (315.45 M) with loss before overhead, payroll, taxes, and interest of (180.29 M).
Beam Therapeutics has a poor financial position based on the latest SEC disclosures
Over 87.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease - Yahoo Finance
Thematic IdeaBiotech (view all)
Average Analyst Recommendation
Analysts covering Beam Therapeutics report their recommendations after researching Beam Therapeutics' financial statements, talking to executives and customers, or listening in on Beam Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Beam Therapeutics. The Beam Therapeutics consensus assessment is calculated by taking the average forecast from all of the analysts covering Beam Therapeutics.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Beam Therapeutics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Beam Therapeutics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted69.3 M64.2 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares69.3 M64.2 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities230.3 M213.4 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities698.9 M647.7 M
Significantly Up
Increasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Total Debt121.2 M147.6 M
Significantly Down
Increasing
Slightly volatile
Asset Turnover0.05810.0538
Significantly Up
Increasing
Slightly volatile
Current Assets1.4 B1.3 B
Significantly Up
Increasing
Slightly volatile
Total Assets1.6 B1.5 B
Significantly Up
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Beam Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Beam Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Beam Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Beam Therapeutics' financial leverage. It provides some insight into what part of Beam Therapeutics' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Beam Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Beam Therapeutics deploys its capital and how much of that capital is borrowed.
Liquidity
Beam Therapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 178.5 M in liabilities with Debt to Equity (D/E) ratio of 0.25, which may suggest the company is not taking enough advantage from borrowing. Beam Therapeutics has a current ratio of 4.55, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Beam Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Beam Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Beam Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Beam Therapeutics to invest in growth at high rates of return. When we think about Beam Therapeutics' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(71.5 Million)
Beam Therapeutics (BEAM) is traded on NASDAQ Exchange in USA and employs 507 people. The company currently falls under 'Mid-Cap' category with current market capitalization of 3.12 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Beam Therapeutics's market, we take the total number of its shares issued and multiply it by Beam Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Beam Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 70.47 M outstanding shares of which 13.01 M shares are currently shorted by private and institutional investors with about 13.39 trading days to cover. Beam Therapeutics currently holds about 1.09 B in cash with 93.55 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.9.
Check Beam Therapeutics Probability Of Bankruptcy
Ownership
Beam Therapeutics holds a total of seventy million four hundred seventy thousand outstanding shares. The majority of Beam Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Beam Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Beam Therapeutics. Please pay attention to any change in the institutional holdings of Beam Therapeutics as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Beam Therapeutics Ownership Details

Beam Therapeutics Stock Price Odds Analysis

Based on a normal probability distribution, the odds of Beam Therapeutics jumping above the current price in 90 days from now is about 88.03%. The Beam Therapeutics probability density function shows the probability of Beam Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.9459 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Beam Therapeutics will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Beam Therapeutics is significantly underperforming DOW.
  Odds Below 43.01HorizonTargetOdds Above 43.01
11.90%90 days
 43.01 
88.03%
Based on a normal probability distribution, the odds of Beam Therapeutics to move above the current price in 90 days from now is about 88.03 (This Beam Therapeutics probability density function shows the probability of Beam Therapeutics Stock to fall within a particular range of prices over 90 days) .

Beam Therapeutics Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Beam Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Beam Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Beam Therapeutics' value.
InstituionSecurity TypeTotal SharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares10.6 K412 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares9.6 K550 K
View Beam Therapeutics Diagnostics

Beam Therapeutics Historical Income Statement

Beam Therapeutics Income Statement is one of the three primary financial statements used for reporting Beam Therapeutics's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Beam Therapeutics revenue and expense. Beam Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Beam Therapeutics Weighted Average Shares is relatively stable at the moment as compared to the past year. The company's current value of Weighted Average Shares is estimated at 69.3 Million. Weighted Average Shares Diluted is expected to hike to about 69.3 M this year, although the value of Earning Before Interest and Taxes EBIT will most likely fall to (380.4 M). View More Fundamentals

Beam Therapeutics Stock Against Markets

Picking the right benchmark for Beam Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Beam Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Beam Therapeutics is critical whether you are bullish or bearish towards Beam Therapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Beam Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Analysis Now

   

Equity Analysis

Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
All  Next Launch Module

Invested in Beam Therapeutics?

The danger of trading Beam Therapeutics is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Beam Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Beam Therapeutics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Beam Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Trending Equities. Note that the Beam Therapeutics information on this page should be used as a complementary analysis to other Beam Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for Beam Therapeutics Stock analysis

When running Beam Therapeutics price analysis, check to measure Beam Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Beam Therapeutics is operating at the current time. Most of Beam Therapeutics' value examination focuses on studying past and present price action to predict the probability of Beam Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Beam Therapeutics' price. Additionally, you may evaluate how the addition of Beam Therapeutics to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Is Beam Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam Therapeutics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
3.1 B
Quarterly Revenue Growth YOY
19.71
Return On Assets
(0.08) 
Return On Equity
(0.40) 
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam Therapeutics that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Beam Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.